Protara Therapeutics, Inc. announced a public offering of 13,043,479 shares of common stock at $5.75 per share, totaling around $75 million before expenses. The underwriters have an option to purchase an additional 1,956,521 shares. The offering, expected to close on December 8, 2025, will fund the clinical development of TARA-002 and other programs. Proceeds may also be used for working capital and general corporate purposes.